Early treatment with a biosimilar agent increased total costs by £70 (US $89) per patient versus standard intervention.
In patients with rheumatoid arthritis (RA), early treatment with biologics can have substantial benefits; anti—tumor necrosis factor (anti-TNF) therapies, for example, increase the likelihood of remission and slow radiographic progression. The cost of biologics, however, means that many patients lack access to these agents.
In a newly published paper, a team of authors sought to assess the cost-effectiveness of early treatment with biologics—either reference or biosimilar—in patients who do not respond adequately to conventional drugs.
Using a Markov model to estimate lifetime patient costs, the researchers compared standard intervention (adding an anti-TNF agent to methotrexate after 12 months) with 2 early intervention options (adding an anti-TNF reference at 6 months or adding an anti-TNF biosimilar at 6 months).
Adding a reference anti-TNF agent after 6 month of methotrexate increased costs by £4701 (US $5978) per patient versus the standard intervention but decreased lifetime direct costs (such as medical costs) and indirect costs (such as loss of work productivity) by £3008 (US $3826) per patient. Overall, this intervention yielded a net cost increase of £1692 (US $2151) per patient.
Adding a biosimilar anti-TNF agent resulted in the same changes in lifetime direct and indirect costs, but resulted in a lower increase in treatment cost at £3078 (US $3914) per patient. Compared with standard intervention, total costs were increased in this scenario by £70 (US $89) per patient.
There was an increase of 0.10 quality-adjusted life years (QALYs) in patients who received early treatment, from 5.4 QALYs for the standard intervention to 5.5 QALYs for early therapy.
Early intervention versus standard intervention was shown to be cost-effective at a threshold of £30,000 (US $38,147) per QALY, with incremental cost-effectiveness ratios (ICERs) of £17,335 (US $22,042) per QALY for reference anti-TNF agents and £713 (US $907) per QALY with biosimilars.
While additional research is warranted, say the authors, this analysis is an important first step in research on early biologic therapy for patients with RA, and suggest that early biologic or biosimilar intervention is cost-effective and carries very low ICERs.
Reference
Patel D, Shelbaya A, Cheung R, Aggarwal J, Park SH, Coindreau J. Cost-effectiveness of early treatment with originator biologics or their biosimilars after methotrexate failure in patients with established rheumatoid arthritis [published online May 30, 2019]. Adv Ther. doi: 10.1007/s12325-019-00986-7.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.